SOPHiA GENETICS SA·4

Jun 22, 4:01 PM ET

HIRSCH DIDIER 4

Research Summary

AI-generated summary

Updated

SOPHiA GENETICS (SOPH) Director Didier Hirsch Receives Stock Awards

What Happened

  • Didier Hirsch, a director of SOPHiA GENETICS SA (SOPH), was granted two equity awards on June 18, 2026: 19,724 restricted stock units (RSUs) valued at $5.46 each ($107,693) and 28,818 derivative awards (share options) valued at $5.46 each ($157,346). Total granted: 48,542 shares with an aggregate value of $265,039. These are awards/compensation (not open‑market purchases or sales).

Key Details

  • Transaction date: June 18, 2026. Filing date (Form 4): June 22, 2026.
  • Price/value reported: $5.46 per share; totals $107,693 (RSUs) and $157,346 (options); combined $265,039.
  • Shares owned after transaction: Not specified in the provided filing details.
  • Footnotes: F1 — 19,724 RSUs granted; each RSU converts to one ordinary share and vests 100% as of the issuer’s next scheduled annual meeting, subject to continued service. F2 — 28,818 share options granted; vest 100% as of the issuer’s next scheduled annual meeting, subject to continued service.
  • Filing timeliness: Form 4 was filed June 22, 2026, reporting the June 18 transaction. (Check official filing for any late‑filing designation.)

Context

  • These entries are grants (compensation) rather than purchases or exercises. The derivative entry represents an option award (a future right to receive shares if/when vested/exercised), not an immediate share sale or cashless exercise. Such awards are routine forms of director compensation and do not by themselves indicate the insider is buying or selling shares in the market.